Background. Postpartum haemorrhage (PPH) can be exacerbated by haemostatic failure. Based on data from trauma studies, empirical infusions of fresh frozen plasma (FFP) are often given during severe PPH if coagulation tests are unavailable. This study observed a cohort of women with moderate/severe PPH in whom FFP infusion was guided by the use of viscoelastometric point-of-care testing (VE-POCT) and clinical assessment. Methods. Women were enrolled into this observational study when blood loss was measured or suspected to be about 1000 mL. If Fibtem A5 determined by Rotem V R thromboelastometry remained >15 mm, or bleeding stopped, FFP was withheld. If Fibtem A5 was 15 mm and bleeding ongoing, women were randomized into an interventional study as previously reported. Clinical and laboratory outcomes were recorded. Results. The study recruited 605 women and 98% had FFP withheld. The median (25
Postpartum haemorrhage (PPH) is precipitated predominantly by obstetric causes but can be exacerbated by haemostatic impairment. Some bleeds resolve before clinically significant coagulopathy develops, whilst others are associated with severe haemostatic impairment. The likelihood of coagulopathy depends on the cause and size of the bleed. [1] [2] [3] The Royal College of Obstetrics and Gynaecology (RCOG) defines established haemostatic impairment as ongoing bleeding associated with a prothrombin time (PT), or activated partial thromboplastin time (aPTT) >1.5 times normal and recommend infusing fresh frozen plasma (FFP) to maintain PT/aPTT below this ratio. 4 Guidelines recommend maintaining a fibrinogen >2 g L À1 and, if bleeding has stopped, no blood product replacement is required. 2 4 Haemostatic impairment can evolve rapidly, and routine laboratory coagulation tests are often not available soon enough to be clinically useful. Clinicians, therefore, might not know whether a coagulopathy is developing. 5 This has led to guidelines recommending empirical fixed-ratios of red blood cells (RBC) and FFP to manage PPH. 2 4 6-8 This strategy is based on data derived from trauma studies with limited evidence in PPH. [9] [10] [11] The haemostatic system at term is hypercoagulable compared with the healthy non-pregnant population, 1 3 so trauma-induced-coagulopathy differs markedly from the coagulopathy associated with PPH. 12 13 It might be inappropriate, therefore, to extrapolate treatment strategies from trauma to PPH. Fixed-ratio transfusion can result in unnecessary transfusion of FFP, which can be associated with complications such as transfusion associated circulatory overload and allergic reactions. 12 14-16 During PPH, fibrinogen decreases earlier than other coagulation factors 17 suggesting that if fibrinogen is maintained then other coagulation factors will be adequate. A viscoelastometric point-of-care test (VE-POCT), Fibtem A5 performed on the RotemV R machine, is a surrogate measure of fibrinogen with results available within 10 min. Fibtem A5 correlates with laboratory fibrinogen during PPH 18 and is predictive of progression from moderate to severe PPH. 19 The aim of the OBS2 study was to investigate a cohort of women experiencing moderate to severe PPH. Women with Fibtem A5 15 mm (Clauss fibrinogen $ 3g L À1 ) 18 19 and ongoing bleeding were eligible to be randomized to the interventional part of the study comparing the effectiveness of fibrinogen concentrate or placebo. The randomized women showed that, if plasma fibrinogen was >2 g L À1 or Fibtem A5 >12 mm, infusion of fibrinogen concentrate did not affect outcomes. 20 The protocol instructed that for women in whom Fibtem A5 was >15 mm, or in whom bleeding had stopped, FFP should be withheld. These women are reported here.
Methods
This was an observational study conducted in teaching hospital obstetric units, and formed part of a multicentre trial to randomize women to fibrinogen or placebo. The protocol is published. 21 Trial registration: ISRCTN46295339 (http://www.
isrctn.com/ISRCTN46295339) (accessed July 24, 2017), EudraCT 2012-005511-11 (https://www.clinicaltrialsregister.eu/ctrsearch/search?query¼2012-005511-11) (accessed July 24, 2017). The study was approved by Edinburgh, Multicentre Research Ethics Committee (13/SS/0008).
Women age !18 yr and !24 weeks gestation experiencing major PPH (measured or suspected blood loss of $1000 mL) could be enrolled. Women were excluded if they declined blood transfusion, had placenta accreta diagnosed antenatally or there was clinical suspicion of amniotic fluid embolus. 21 Women received written information in their maternity notes. Verbal consent to participate was sought at enrolment and confirmed in writing once the woman had recovered. At study entry Fibtem assay was performed on delivery suite and samples sent to the laboratory for a full blood count (FBC), Clauss fibrinogen, PT and aPTT. Blood loss was estimated gravimetrically as described. 22 If the A5 was 15 mm, the baby delivered and bleeding ongoing, the woman was randomized to fibrinogen concentrate or placebo. If the A5 was >15 mm local standard treatment for PPH was given except that FFP should not have been infused (cryoprecipitate infusion was not excluded). Fibtem was repeated after each additional 500 mL blood loss or for clinical concern, and FFP continued to be withheld if A5 remained !15 mm or if bleeding stopped (Fig. 1) . Information was collected electronically. A full description of data points has been published. 21 Analysis of the observational group reported here was descriptive and no hypotheses were tested, therefore, a sample size calculation was not conducted. Established laboratory haemostatic failure was defined in accordance with RCOG guidelines as PT or aPTT >1.5 times the midpoint of the normal range (in this study !16.5 s and !48 s, respectively) or a fibrinogen <2 g L À1 . 4 Clinically significant haemostatic impairment was defined as established laboratory haemostatic failure associated with continuing bleeding. Level 3 care was advanced respiratory support or receiving 2 other organs support (usually renal or cardiac).
Editor's key points
• Guidelines recommend empiric plasma transfusion for postpartum haemorrhage (PPH) with haemostatic impairment.
• The effect of point-of-care thromboelastometry-guided plasma transfusion in women with moderate to severe postpartum haemorrhage was analysed.
• Restricted use of plasma based on thromboelastometry results was feasible and did not result in significant haemostatic impairment.
Descriptive summaries of maternal characteristics at study entry by cohort (observational or intervention) were performed and the means of continuous variables were compared using Student's t-test for continuous variables (Mann-Whitney U-test for non-normal distributions), and proportions of the binary variables were compared using the v 2 test. Analyses were performed using SPSS version 23 (IBM SPSS Inc, Chicago, USA).
Results
The observational study cohort comprised 606 women with moderate to severe PPH recruited between 29 th June 2013 and 26 th November 2015, who were not eligible to be randomized to the interventional trial because either their Fibtem A5 remained >15 mm or bleeding stopped. One woman withdrew consent, therefore, 605 women are reported who were managed though the observational arm of the protocol and should have had FFP withheld (Fig. 2) . The outcomes of the 57 women recruited to the interventional arm are reported elsewhere. 20 Subject characteristics at enrolment, mode of delivery and cause of bleeding are shown in Table 1 , enrolment characteristics of the women who were randomized are shown for comparison. Women in the observational group had smaller bleeds at study entry and, as a direct consequence of study design, had higher fibrinogen and Fibtem A5 than the interventional group although PT and aPTT were similar.
The outcomes of women in the observational group are shown in Table 2 Women with laboratory tests associated with established haemostatic failure
The longest PT, aPTT and lowest fibrinogen are shown in Table 2 . Where data were available, 3/537 (0.6%) had a PT ratio >1.5, 0/544 (0%) had an aPTT >1.5 and 6/544 (1.1%) had a fibrinogen <2 g L À1 at some time during the study. Eight women developed laboratory evidence of established haemostatic failure as defined by RCOG 4 ( 
Women who received FFP or were admitted to level 3 care
Twelve women (2.0%) received between 1-4 units of FFP despite this being contrary to the protocol. Individual details of coagulation tests, blood products received and outcomes are described in (Table 4) . Ten/605 women (1.7%) were admitted to level 3 care, four of whom received FFP and one cryoprecipitate (Table 4 ). In the seven women on whom data were available, none had laboratory evidence of established haemostatic impairment or a low Fibtem.
Women with a total measured blood loss more than 2500 mL Forty/605 (6.6%) women bled >2500 mL. Five women also received FFP and are reported in detail in Table 4 . In the 35 women who did not receive FFP, median (25 th to 75 th centile, range) blood loss was 3000 (2700-3000, 2530-5500) mL and the lowest Fibtem A5 was 19 (16-22, 10-34) mm. The lowest laboratory fibrinogen (known for 32) was 3.4 (2.4-4.6, 2.3-6) g L
À1
. None of the women for whom data were available (n¼32) had laboratory evidence of established haemostatic failure at any time, and lowest Fibtem A5s in the other three women were 20, 22 and 34 mm. In total 24/35 (68.6%) received RBCs and 23/35 (65.7%) had between one and four invasive procedures to control bleeding. Five/35 (14.2%) women had a Fibtem A5 15 mm but bleeding stopped soon afterwards and so they were not randomized. One woman bled an additional 1500 mL after the Fibtem A5 was 11 mm. She bled a total of 3000 mL in 25 min because of uterine atony which was controlled with an intrauterine balloon. The Fibtem A5 result of 11 mm was available about 10 min before the bleeding stopped and hence she was not randomized; she received four units of RBC and no FFP. A lower proportion of the observational group had placental abruption than the interventional group. This might be explained because abruption is known to be associated with reduced fibrinogen, 1 23-25 and this precipitated randomization.
In contrast, the observational group had a higher proportion of bleeds as a result of genital tract trauma, which is known to be less often associated with reduced fibrinogen. 19 26 The observational group had higher laboratory fibrinogen and Fibtem values at study entry as dictated by the study design. Despite this, PT and aPTT values were similar between the observational and randomized groups. This supports previous observations that fibrinogen decreases earlier than other coagulation factors during PPH, 17 and that adequate fibrinogen can be used as a surrogate for normal laboratory haemostasis during PPH. The women who were not randomized had better outcomes than the women who were. This is because the two groups were stratified by Fibtem A5 and Clauss fibrinogen levels which are known to be predictive of progression of PPH. 19 27-29 The difference in outcomes between the two groups does not allow conclusions to be drawn on whether restrictive use of FFP based on Fibtem A5, as described here, is an appropriate treatment strategy. Guidelines recommend maintaining PT and aPTT <1.5 times normal and fibrinogen >2 g L À1 . 2 4 8 The randomized arm of this study showed that if Fibtem A5 was >12 mm or Clauss fibrinogen >2 g L À1 , infusion of fibrinogen concentrate did not affect outcomes, supporting the conclusion that a fibrinogen of 2 g L
(or Fibtem >12 mm) is adequate for haemostasis during PPH. 20 In the cohort of women reported here, FFP was withheld if the Fibtem A5 remained >15 mm, or a fibrinogen of about 3 g L
. 20 Only eight women subsequently developed laboratory evidence of established haemostatic failure. In all of these patients Fibtem A5 was 15 mm but bleeding stopped soon after enrolment through obstetric intervention, indicating that bleeding was not caused primarily by coagulopathy. Therefore, withholding FFP guided by Fibtem did not result in clinically significant haemostatic impairment because bleeding was controlled with obstetric intervention in all cases.
Twelve women received FFP and it is not possible to be certain whether FFP infusion influenced outcomes in these women. In nine patients FFP was infused when bleeding had stopped and tests of haemostasis were normal, therefore giving FFP is unlikely to have influenced outcomes. FFP infusion in these patients could have been influenced by human factors such as concern about the risk of further bleeding or the desire not to waste FFP that had been thawed. The study involved a large number of investigators and these factors could have varied between individuals.
None of the 40 women with a total blood loss >2500 mL developed laboratory evidence of established haemostatic failure, and it is unlikely that fibrinogen or FFP infusion would have reduced bleeding. Clinicians would not have known the results of laboratory coagulation tests for about 60 min, therefore, early knowledge of Fibtem A5 appears to have been useful in managing blood product replacement, even in women with massive PPH. If a strategy of empirical, fixed-ratio FFP had been used, some of these women would have been exposed to FFP because 73% received RBCs. These findings suggest that withholding FFP based on clinical assessment of bleeding and the Fibtem A5 is unlikely to result in clinically significant haemostatic impairment.
None of the 10 women admitted to level 3 care had Fibtem 15 mm or laboratory tests consistent with established haemostatic failure, although four received FFP and one cryoprecipitate. It is unlikely that a more liberal use of FFP would have improved outcomes, however it is not possible to determine whether giving FFP influenced outcomes unrelated to haemostasis, for example development of respiratory complications. Of the four women admitted to level 3 care for respiratory distress or fluid overload, three had received FFP and one had not. Some of the women had received large volumes of fluids, although this did not lead to evidence of haemostatic failure. No data were collected on catecholamine usage. Careful review of fluid balance is an important part of the management of PPH. 4 8 The 605 women reported in this study are a selected cohort because women with ongoing bleeding and Fibtem A5 15 mm entered the randomized study. In the whole OBS2 study (the cohort reported here and the randomized women combined), 27% received RBCs, 4.1% received !4 units RBC and 9.2% had total blood loss >2500 mL. In our previously published, unselected, consecutive cohort of 356 women recruited with similar inclusion criteria, 30% received RBC transfusion, 9% received !4 units RBC and 11% had a bleed of >2500 mL. 19 This suggests that some women with larger bleeds were not recruited into the study compared with an unselected cohort of women with PPH. It is likely, therefore, that a higher proportion of women with PPH would develop a coagulopathy than reported here because some cases of severe bleeding, where coagulopathy can develop rapidly, appear to be underrepresented in this study. A strength of this study is the large number of women treated on a standardized haemostasis management protocol. There was good compliance with the protocol despite involvement of many clinicians, with varying levels of experience, at multiple sites suggesting that it is feasible to integrate VE-POCT into management of PPH. The main weaknesses are that the study is observational and there is no control arm of women who received fixed-ratio RBC:FFP transfusion for comparison. It remains possible that a more liberal use of FFP, as recommended by many clinicians, 6 7 9 10 would have prevented some women developing haemostatic impairment and entering the randomized arm of the study. Some critically unwell women were not recruited because clinicians could not follow trial procedures whilst managing these challenging patients. Whether restrictive use of FFP, guided by VE-POCTs, is appropriate for these women is unknown and requires future study.
Conclusions
In a cohort of women with PPH, restrictive use of FFP based on clinical observation of bleeding and Fibtem A5 is feasible and did not result in clinically significant haemostatic impairment. Studies that recruit women with all severities of PPH are needed to compare the clinical and cost effectiveness of liberal, empirical use of FFP, as recommended by current guidelines, 2 4 8 with restrictive use of FFP and early fibrinogen replacement based on point-of-care testing. 
